Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.34 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.34 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.34 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.33 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27082801 | 0.87 | KMT2A (0.40) | NPC1RAB9ASMN1; SMN2LMNASLC6A1 | |
| SCHEMBL27082804 | 0.87 | KMT2A (0.40) | NPC1RAB9ASMN1; SMN2LMNASLC6A1 | |
| SCHEMBL27082993 | 0.87 | NPC1 (0.38) | PLA2G2APLA2G10PLA2G1BPLA2G5NPC1 | |
| SCHEMBL27082995 | 0.87 | NPC1 (0.38) | PLA2G2APLA2G10PLA2G1BPLA2G5NPC1 | |
| SCHEMBL29894147 | 0.82 | PLA2G2A (0.35) | PLA2G2APLA2G10PLA2G1BPLA2G5NPC1 | |
| SCHEMBL27250464 | 0.77 | NPC1 (0.31) | PLA2G2APLA2G10PLA2G1BPLA2G5NPC1 | |
| SCHEMBL29142567 | 0.76 | KIF11 (0.39) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL27250454 | 0.75 | — | — | |
| SCHEMBL29142569 | 0.74 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2LMNASLC6A1 | |
| SCHEMBL27250521 | 0.73 | KIF11 (0.43) | NPC1RAB9ASLC6A1SLC6A11KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209018-A1 | UNIVERSAL LINKER REAGENTS FOR DNA SYNTHESIS | GENSCRIPT USA INC. | 2024-06-27 | — | — | US | disclosed |
| EP-4313984-A1 | UNIVERSAL LINKER REAGENTS FOR DNA SYNTHESIS | Genscript USA Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022204102-A1 | UNIVERSAL LINKER REAGENTS FOR DNA SYNTHESIS | GENSCRIPT USA INC. (US) | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209018-A1 | UNIVERSAL LINKER REAGENTS FOR DNA SYNTHESIS | RNGTT, DTYMK, UNG | PLA2G2A 2201/4885PLA2G10 2465/4885PLA2G1B 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.